On May 4, 2020, Vir Biotech and Alnylam Pharma announced announced the selection of a development candidate for VIR-2703, an investigational RNAi therapeutic targeting the SARS-CoV-2 genome. The companies plan to meet with the FDA and other regulatory authorities to discuss a potential accelerated path for filing an Investigational New Drug or IND equivalent application at or around year-end 2020, less than a year since program initiation. The companies plan to advance VIR-2703 as an inhalational formulation for the potential treatment and/or prevention of COVID-19.